Operational Mastery: Scaling Boutique CRO with Lessons from the Frontlines

An interview with Alina Tatarenko, Head of Clinical Operations at Palleos

What does it take to steer the clinical operations of a growing CRO in today’s complex landscape? It requires a unique blend of large-CRO discipline and agile, niche-CRO flexibility.

Alina Tatarenko, Head of Operations at Palleos, leverages 23 years of experience including from global leaders like ICON to drive the company’s growth. She shares the strategic operational changes made to scale Palleos effectively. Alina doesn’t shy away from the hard lessons, sharing a pivotal learning moment from past project challenges and how it directly shapes protocols today. Read on for a masterclass in pragmatic, forward-thinking clinical operations leadership.

With your 23 years of experience including at giants like ICON, what was the most significant cultural shift in moving to a more boutique, mid-size CRO like Palleos, and how has it changed your approach to managing operations?

The most significant shift for me was realizing that in a boutique CRO like Palleos, every team member’s impact is magnified. Unlike global giants, here each individual truly becomes a critical pillar of our success. This environment has allowed me to amplify my focus on empowering team members to become strong, decision-making partners for our clients and sites. Transitioning to Palleos has been energizing; the decision-making process is refreshingly nimble, enabling us to act quickly and innovatively. My focus is now on strengthening our team of high-level professionals who are strategic partners, leveraging our agility as a core strength. Working with a smaller, highly skilled group allows me to mentor directly, spot talent faster, and create tailored development opportunities.

Finally, close partnership with our clients is a key pillar of our approach at Palleos. We are deeply committed to building these relationships from the very beginning of each project, doing everything possible to foster open communication, anticipate needs, and deliver truly personalized, responsive solutions.

You joined Palleos to lead clinical research operations. What are the first three strategic areas you identify as a priority? 

Streamlining processes reviewing and further optimizing our operational processes is my first priority. By working closely with the team, we’re identifying opportunities to eliminate bottlenecks and enhance efficiency, ensuring our workflows remain both compliant and agile. These improvements support faster project start-up times and smoother execution.

Next is enhancing quality and risk management infrastructure. Building on Palleos’ strong foundation, I have prioritized evolving our quality and risk management approach from robust oversight to a truly proactive, centralized model. This includes formalizing RBQM practices and establishing regular cross-functional risk review meetings, ensuring that quality is embedded by design and that potential challenges are anticipated early.

Regarding investing in our team’s strategic development, I am committed to developing our operational talent beyond clinical execution, focusing on client management, strategic thinking, and data-driven decision-making. Empowering our team at every level helps maintain our agility and ensures we consistently deliver expert, responsive service as we grow.

Reflecting on your experience with complex projects, what is the most significant lesson you’ve gained that has profoundly shaped your approach to managing operations at Palleos?

First of all, I would highlight embracing flexibility and out-of-the-box thinking. Complex projects taught me that even meticulous plans can be disrupted. I’ve learned to prioritize flexibility and foster a culture where creative, compliant solutions are encouraged. This ensures rapid adaptation and proactive problem-solving, leading to high-quality outcomes.

Furthermore, a key principle for me is staying compliant, with a ‘why and what’s next’ approach. Understanding the reasoning behind rules and anticipating future changes helps us make informed, innovative, and quality-driven decisions, positioning Palleos to stay ahead.

In addition to that, I place great emphasis on building an empowered team. My experiences have reinforced the value of enabling team members to make decisions, propose ideas, and take ownership. An empowered team is agile, resilient, and deeply invested in delivering exceptional results.

And finally, transparent communication is the foundation of everything. Honest, open, and timely communication — internally and externally — builds trust, keeps everyone aligned, and ensures small issues are addressed before they become major obstacles, safeguarding the quality of our deliverables.

Can you share your approach to adopting advanced technologies such as AI at Palleos, and how do you balance innovation with risk management in daily operations? How does Palleos leverage AI in its day-to-day work, and what safeguards do you put in place?

At Palleos, we consider AI as a valuable support tool. It assists with tasks ranging from drafting meeting minutes and information searches to complex activities like analyzing site selection data, predicting patient recruitment, and supporting data analysis.

However, innovation is balanced with responsibility. Before implementing any AI tool, we rigorously test it for reliability and regulatory compliance. Our quality and operations teams jointly evaluate risks and establish clear usage protocols. Crucially, our staff are trained to critically review all AI outputs and apply human judgment where needed.

We actively monitor the evolving AI landscape to ensure we follow best practices. For us, AI is not about replacing human critical thinking but about freeing our experts from routine tasks, allowing them to focus on strategic tasks. This approach ensures we benefit from technological advances while keeping all key decisions in the hands of experienced professionals.

What opportunities do the European Biotechnology Act and EMA’s new clinical trial targets present for sponsors, and how is Palleos positioning itself in response?

The European Biotechnology Act and the EMA’s new clinical trial targets are truly reshaping the clinical research landscape in the EU, making it more competitive and innovation-friendly. For sponsors, this creates several key opportunities. The Biotech Act aims to simplify and streamline clinical trial assessments, which should significantly reduce approval timelines. This is a major step forward, especially for advanced therapies. At the same time, the EMA is pushing to increase the number of multinational trials and ensure that most begin patient recruitment within 200 days. There’s even active discussion about moving towards a 60-day review window. What this means for sponsors is a more harmonized regulatory framework, faster access to diverse patient populations, and a stronger emphasis on supporting innovation in areas like real-world evidence and digital tools.

In response, Palleos is proactively positioning itself. We are adapting our operational models and SOPs to align with these new frameworks from day one, ensuring rapid and compliant clinical research trial start-ups. We’re also expanding our expertise in advanced therapies and investing in digital tools to enhance our operations, all while maintaining our strong focus on quality and compliance. Our team is closely monitoring these regulatory shifts, allowing us to guide our clients confidently through this evolving landscape and help them turn these new regulatory opportunities into tangible operational success.